657425-05-3

Basic information

• Product Name: Silane, [(5-chloro-2-fluorophenyl)ethynyl]trimethyl-
• CAS NO: 657425-05-3
• Molecular Formula: C11H12ClFSi
• Molecular Weight: 226.753
• Mol File: 657425-05-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Silane, [(5-chloro-2-fluorophenyl)ethynyl]trimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Silane, [(5-chloro-2-fluorophenyl)ethynyl]trimethyl-(657425-05-3)
• EPA Substance Registry System: Silane, [(5-chloro-2-fluorophenyl)ethynyl]trimethyl-(657425-05-3)

Safety Data

• Hazardous Substances Data: 657425-05-3(Hazardous Substances Data)

Upstream product

• 1996-30-1 2-bromo-4-chloro-1-fluorobenzene 
• 1066-54-2 trimethylsilylacetylene 

Downstream Products

• 657425-19-9 methanesulfonic acid 1-[5-(5-chloro-2-fluoro-phenyl)-isoxazol-3-yl]-ethyl ester 
• 657425-17-7 methanesulfonic acid 5-(5-chloro-2-fluoro-phenyl)-isoxazol-3-ylmethyl ester 
• 657425-09-7 5-(5-chloro-2-fluoro-phenyl)-isoxazole-3-carboxylic acid ethyl ester 
• 657425-07-5 4-chloro-2-ethynyl-1-fluorobenzene 

Relevant articles and documents

ALK5 INHIBITORS

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use therefor for effectively treating and/or preventing FGFR-related diseases such as tumors

The present invention relates to an alkynyl-substituted heterocyclic compound serving as an FGFR inhibitor, a preparation method therefor and a medical use therefor. In particular, the present invention relates to a compound represented by the general formula (I) and its pharmaceutically acceptable salt, a pharmaceutical composition including the compound or its pharmaceutically acceptable salt, a method for treating and/or preventing FGFR-related diseases, particularly tumors, by using the compound or its pharmaceutically acceptable salt, and a preparation method of the compound or its pharmaceutically acceptable salt. The present invention also relates to an use of the compound or its pharmaceutically acceptable salt, or an pharmaceutical composition including the compound or its pharmaceutically acceptable salt in the preparation of a drug for treating and/or preventing FGFR-related diseases, particularly tumors, wherein the definition of each substituent in the general formula (I) is the same as that in the specification.

NEW COMPOUNDS

The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, R, R1, R2, R3, R4, R5, R6, R7, m, n, o, p and q are defined as in any one of claims 1 to 12, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.